Hutchison China Meditech Share Price (NASDAQ: HCM)

$16.05

▲

-0.06

(-0.37%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Hutchison China Meditech Stock chart to analyse performance

Hutchison China Meditech stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$16.05
Today's High:$16.25
$16.05
0.0%
Downside
Day's Volatility :1.23%
Upside
1.23%
52 Weeks Low:$11.51
52 Weeks High:$21.50
$16.05
28.32%
Downside
52 Weeks Volatility :46.49%
Upside
25.35%

Hutchison China Meditech Stock Returns

Period	Hutchison China Meditech Limited	Sector (Health Care)	Index (Russel 2000)
3 Months	19.39%	6.0%	0.0%
6 Months	3.96%	-5.6%	0.0%
1 Year	-7.24%	-11.1%	0.0%
3 Years	27.57%	6.8%	-7.8%

Hutchison China Meditech Limited Key Stats

Check Hutchison China Meditech key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$16.11
Open	$16.24
Today's High	$16.25
Today's Low	$16.05
Market Capitalization	$2.8B
Today's Volume	$62.4K
52 Week High	$21.5
52 Week Low	$11.505
Revenue TTM	$602.2M
EBITDA	$-7.5M
Earnings Per Share (EPS)	$2.65
PE Ratio	6.08
Profit Margin	77.53%
Quarterly Earnings Growth YOY	16.33%
Return On Equity TTM	46.9%

Stock Returns calculator for Hutchison China Meditech Stock including INR - Dollar returns

The Hutchison China Meditech stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Hutchison China Meditech investment value today

Current value as on today

₹97,305

Returns

₹2,695

(-2.69%)

Returns from Hutchison China Meditech Stock

₹7,010 (-7.01%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Hutchison China Meditech Stock

100%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Hutchison China Meditech Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Hutchison China Meditech Limited

Name
Holdings %
Name
Holdings %
Schroder Investment Management Group
1.50%
Allianz Asset Management AG
0.58%
State Street Corp
0.20%
AIA Group Ltd
0.18%
Goldman Sachs Group Inc
0.17%
M&G PLC
0.15%

Analyst Recommendation on Hutchison China Meditech Stock

Rating

Trend

Buy

90%Buy

9%Hold

0%Sell

Based on 22 Wall street analysts offering stock ratings for Hutchison China Meditech(by analysts ranked 0 to 5 stars)

Hutchison China Meditech Share Price Target

What analysts predicted

Upside of 45.75%

Target:

$23.39

Current:

$16.05

Hutchison China Meditech share price target is $23.39, a slight Upside of 45.75% compared to current price of $16.05 as per analysts' prediction.

Hutchison China Meditech Stock Insights

Price Movement
In the last 7 days, HCM stock has moved down by -2.7%
Increasing Revenue
Revenue is up for the last 5 quarters, 152.56M → 162.26M (in $), with an average increase of 1.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 12.90M → 5.96M (in $), with an average decrease of 26.9% per quarter
HCM vs HLN (1 yr)
In the last 1 year, Hutchison China Meditech Limited has experienced a drawdown of -7.2%, however Haleon Plc Spon Ads resisted the overall trend and outperformed by 6.3%
HCM vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 53.8% return, outperforming this stock by 23.7%
Price to Sales
ForHCM every $1 of sales, investors are willing to pay $4.5, whereas for Haleon Plc Spon Ads, the investors are paying $4.0 for every $1 of sales.

Hutchison China Meditech Limited Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$204.9M	↓ 4.31%
Net Income	$-144.4M	↑ 93.01%
Net Profit Margin	-70.47%	↓ 35.53%

	FY20	Y/Y Change
Revenue	$228.0M	↑ 11.27%
Net Income	$-194.6M	↑ 34.76%
Net Profit Margin	-85.34%	↓ 14.87%

	FY21	Y/Y Change
Revenue	$356.1M	↑ 56.21%
Net Income	$-227.7M	↑ 17.01%
Net Profit Margin	-63.93%	↑ 21.41%

	FY22	Y/Y Change
Revenue	$426.4M	↑ 19.73%
Net Income	$-410.1M	↑ 80.16%
Net Profit Margin	-96.18%	↓ 32.25%

	FY23	Y/Y Change
Revenue	$838.0M	↑ 96.52%
Net Income	$100.8M	↓ 124.57%
Net Profit Margin	12.03%	↑ 108.21%

	FY24	Y/Y Change
Revenue	$630.2M	↓ 24.8%
Net Income	$37.7M	↓ 62.56%
Net Profit Margin	5.99%	↓ 6.04%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Revenue	$152.6M	↓ 42.74%
Net Income	$-33.9M	↓ 140.21%
Net Profit Margin	-22.21%	↓ 53.84%

	Q4 FY23	Q/Q Change
Revenue	$152.6M	↑ 0.0%
Net Income	$-33.9M	↑ 0.0%
Net Profit Margin	-22.21%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$152.8M	↑ 0.18%
Net Income	$12.9M	↓ 138.07%
Net Profit Margin	8.44%	↑ 30.65%

	Q2 FY24	Q/Q Change
Revenue	$152.8M	↑ 0.0%
Net Income	$12.9M	↑ 0.0%
Net Profit Margin	8.44%	↑ 0.0%

	Q3 FY24	Q/Q Change
Revenue	$162.3M	↑ 6.16%
Net Income	$6.0M	↓ 53.77%
Net Profit Margin	3.68%	↓ 4.76%

	Q4 FY24	Q/Q Change
Revenue	$162.3M	↑ 0.0%
Net Income	$6.0M	↑ 0.0%
Net Profit Margin	3.68%	↑ 0.0%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$44.7M	↓ 36.24%

	FY20	Y/Y Change
Profit	$39.5M	↓ 11.8%

	FY21	Y/Y Change
Profit	$97.9M	↑ 148.1%

	FY22	Y/Y Change
Profit	$115.3M	↑ 17.79%

	FY23	Y/Y Change
Profit	$453.6M	↑ 293.35%

	FY24	Y/Y Change
Profit	$281.3M	↓ 37.97%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Profit	$-14.2M	↓ 108.74%

	Q4 FY23	Q/Q Change
Profit	$-14.2M	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$62.8M	↓ 542.59%

	Q2 FY24	Q/Q Change
Profit	$62.8M	↑ 0.0%

	Q3 FY24	Q/Q Change
Profit	$-28.2M	↓ 144.87%

	Q4 FY24	Q/Q Change
Profit	$-28.2M	↑ 0.0%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-80.9M	↑ 146.33%
Investing Cash Flow	$119.0M	↑ 172.05%
Financing Cash Flow	$-1.5M	↓ 81.86%

	FY20	Y/Y Change
Operating Cash Flow	$-62.1M	↓ 23.29%
Investing Cash Flow	$-125.4M	↓ 205.39%
Financing Cash Flow	$296.4M	↓ 19954.92%

	FY21	Y/Y Change
Operating Cash Flow	$-204.2M	↑ 229.04%
Investing Cash Flow	$-306.3M	↑ 144.19%
Financing Cash Flow	$650.0M	↑ 119.28%

	FY22	Y/Y Change
Operating Cash Flow	$-268.6M	↑ 31.52%
Investing Cash Flow	$296.6M	↓ 196.82%
Financing Cash Flow	$-82.8M	↓ 112.73%

	FY23	Y/Y Change
Operating Cash Flow	$219.3M	↓ 181.63%
Investing Cash Flow	$-291.1M	↓ 198.16%
Financing Cash Flow	$48.7M	↓ 158.79%

	FY24	Y/Y Change
Operating Cash Flow	$497.0K	↓ 99.77%
Investing Cash Flow	$-96.1M	↓ 67.01%
Financing Cash Flow	$-30.7M	↓ 163.02%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-3.6M	↓ 103.16%
Investing Cash Flow	$12.4M	↓ 107.86%
Financing Cash Flow	$21.4M	↑ 634.65%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-3.6M	↑ 0.0%
Investing Cash Flow	$12.4M	↑ 0.0%
Financing Cash Flow	$21.4M	↑ 0.0%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-19.9M	↑ 457.48%
Investing Cash Flow	$-2.7M	↓ 121.9%
Financing Cash Flow	$-16.3M	↓ 176.03%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-19.9M	↑ 0.0%
Investing Cash Flow	$-2.7M	↑ 0.0%
Financing Cash Flow	$-16.3M	↑ 0.0%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$20.2M	↓ 201.25%
Investing Cash Flow	$-45.3M	↑ 1567.43%
Financing Cash Flow	$947.5K	↓ 105.82%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$20.2M	↑ 0.0%
Investing Cash Flow	$-45.3M	↑ 0.0%
Financing Cash Flow	$947.5K	↑ 0.0%

Hutchison China Meditech Technicals Summary

Sell

Neutral

Buy

Hutchison China Meditech is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Hutchison China Meditech Limited Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Hutchison China Meditech Limited	-9.96%	3.96%	-7.24%	27.57%	-52.72%
Haleon Plc Spon Ads	-0.41%	-3.35%	-0.91%	55.47%	32.39%
United Therapeutics Corporation	1.94%	-12.81%	-10.25%	40.38%	75.65%
Zoetis Inc.	2.46%	-5.28%	-13.44%	-3.72%	-0.11%
Neurocrine Biosciences Inc.	2.8%	13.62%	-11.44%	26.96%	21.38%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Hutchison China Meditech Limited	6.08	6.08	0.0	1.75	0.47	-0.01	NA	1.43
Haleon Plc Spon Ads	21.8	21.8	3.15	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.18	12.18	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.74	26.74	2.54	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	40.02	40.02	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Hutchison China Meditech Limited	Buy	$2.8B	-52.72%	6.08	77.53%
Haleon Plc Spon Ads	Buy	$44.6B	32.39%	21.8	13.81%
United Therapeutics Corporation	Buy	$14.1B	75.65%	12.18	40.36%
Zoetis Inc.	Buy	$69.0B	-0.11%	26.74	27.83%
Neurocrine Biosciences Inc.	Buy	$13.4B	21.38%	40.02	13.88%

About Hutchison China Meditech Limited

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Organization	Hutchison China Meditech
Employees	1780
CEO	Dr. Wei-Guo Su B.Sc., Ph.D.
Industry	Health Technology

Key Management of Hutchison China Meditech Limited

Name	Title
Dr. Wei-Guo Su B.Sc., Ph.D.	CEO, Chief Scientific Officer & Executive Director
Mr. Chig Fung Cheng BEc, CA	CFO & Executive Director
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E	Company Secretary & Non-Executive Director
Ms. Yiling Cui	Executive VP & Head of Operations
David Ng	Head of Investor Relations & Capital Strategies
Mr. Charles George Rupert Nixon	Group General Counsel
Mr. Kin Hung Lee M.B.A.	Senior Vice President of Corporate Management & Communications
Ms. Selina Zhang	Senior Vice President of Global Human Resources
Dr. Qingmei Wang Ph.D.	Executive Vice President of Business Development & Strategic Alliances
Dr. Zhenping Wu M.B.A, Ph.D.	Executive Vice President of Pharmaceutical Science & Manufacturing

Important FAQs about investing in HCM Stock from India :

What is Hutchison China Meditech share price today?

Hutchison China Meditech share price today is $16.05 as on August 23, 2025 at 1:29 AM IST at the close of the market. Hutchison China Meditech share today touched a day high of $16.25 and a low of $16.05.

What is the 52 week high and 52 week low for Hutchison China Meditech share?

Hutchison China Meditech share touched a 52 week high of $21.50 and a 52 week low of $11.51. Hutchison China Meditech stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $16.05, lower by 25.35% versus the 52 week high.

How to invest in Hutchison China Meditech Stock (HCM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Hutchison China Meditech on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Hutchison China Meditech Shares that will get you 0.0935 shares as per Hutchison China Meditech share price of $16.05 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Hutchison China Meditech Stock (HCM) from India?

Indian investors can start investing in Hutchison China Meditech (HCM) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Hutchison China Meditech stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Hutchison China Meditech share’s latest price of $16.05 as on August 23, 2025 at 1:29 AM IST, you will get 0.6231 shares of Hutchison China Meditech. Learn more about fractional shares .

What are the returns that Hutchison China Meditech has given to Indian investors in the last 5 years?

Hutchison China Meditech stock has given -52.72% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?